Skip to main content
  • About
    • Our Mission
    • Threat of AMR
    • Access and Appropriate Use Principles
    • Our Investors
  • Team
  • Investments
    • How We Invest
    • Our Portfolio
    • Get On Our Radar
  • News
  • Connect

NEWS:

  • All
  • In the News
  • Press Releases
  • Media
  • Fund Resources
July 16, 2026
In the News

Trellis Bioscience Raises $9 Million to Advance Phase 2 Trial of mAb for PJIs

Read More +
July 14, 2026
In the News

The need for innovative financing models for antimicrobial development

Read More +
July 13, 2026
In the News

Sewage overflows and AMR: A growing threat to the Commonwealth

Read More +
July 1, 2026
In the News

Telum Therapeutics raises €18 million to advance treatments for hospital-acquired infections

Read More +
June 24, 2026
In the News

Senators Bennet and Young lead introduction of  PASTEUR Act

Read More +
April 29, 2026
In the News

Op-ed: Antibiotic resistance is growing — don’t delay new antibiotics

Read More +
April 23, 2026
In the News

Op-Ed: Dangerous fungal infections are rising. Will elected officials act?

Read More +
April 20, 2026
In the News

Efforts to Revive Antibiotic Development With PASTEUR Act, Education, Awareness

Read More +
Previous page Next page
contact-bg-img

Connect With Us

Contact
AMR Action Fund Footer Logo

Enabling
Breakthroughs in
Antimicrobials

Stay connected

Stay up-to-date on our work to bring 2 to 4 new antibiotics to patients by the end of the decade. When we have news, we will let you know.

  • About
  • Team
  • Latest
  • Threat of AMR
  • Connect
  • Investments
  • Japan Disclaimer
  • Privacy Policy